|
gptkbp:instanceOf
|
opioid medication
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:ATCCode
|
N02AA03
|
|
gptkbp:bioavailability
|
25% (oral)
|
|
gptkbp:brand
|
gptkb:Norco
gptkb:Lortab
gptkb:Zohydro_ER
gptkb:Vicodin
gptkb:Hysingla_ER
|
|
gptkbp:CASNumber
|
125-29-1
|
|
gptkbp:combines
|
gptkb:ibuprofen
gptkb:aspirin
acetaminophen
|
|
gptkbp:controlledBy
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:C._Mannich
gptkb:Helene_Löwenheim
1920
|
|
gptkbp:discoveredIn
|
gptkb:Germany
|
|
gptkbp:eliminationHalfLife
|
3.8 hours
|
|
gptkbp:hasMolecularFormula
|
C18H21NO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hydrocodone
|
|
gptkbp:IUPACName
|
4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one
|
|
gptkbp:KEGGID
|
D08062
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:marketedAs
|
1943
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:MedlinePlusID
|
a601006
|
|
gptkbp:metabolism
|
gptkb:hydromorphone
gptkb:norhydrocodone
liver
|
|
gptkbp:partOf
|
combination pain medications
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:proteinBinding
|
20–50%
|
|
gptkbp:PubChem_CID
|
4447447
5284569
CHEMBL903
DB00956
|
|
gptkbp:riskFactor
|
overdose
respiratory depression
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
addiction
nausea
constipation
dizziness
drowsiness
|
|
gptkbp:UNII
|
6YKS4Y3WQ7
|
|
gptkbp:usedFor
|
pain relief
cough suppression
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II
|
|
gptkbp:bfsLayer
|
6
|